Roche Advances Antibiotic Zosurabalpin to Phase 3 Trials for Drug-Resistant Acinetobacter Infections

Swiss drugmaker Roche announced on Monday the advancement of its experimental antibiotic, zosurabalpin, into Phase 3 clinical trials. Developed in collaboration with Harvard University, zosurabalpin targets drug-resistant acinetobacter baumannii, a bacterium responsible for severe hospital-acquired infections like pneumonia and sepsis. Roche stated that zosurabalpin utilizes a novel mechanism of action against which bacteria have not yet developed resistance. Acinetobacter infections disproportionately affect hospitalized patients worldwide.